ADRB3 and metabolic dysfunction-associated steatotic liver disease: This study demonstrated that mCPT-1 expression was significantly decreased in NAFLD rats and that β3-AR agonist treatment could upregulate mCPT-1 expression, playing a role in reducing NAFLD liver steatosis.